keyword
MENU ▼
Read by QxMD icon Read
search

programmed-death

keyword
https://www.readbyqxmd.com/read/29053481/programmed-death-ligand-1-expression-among-700-consecutive-endometrial-cancers-strong-association-with-mismatch-repair-protein-deficiency
#1
Zaibo Li, Amy S Joehlin-Price, Jennifer Rhoades, Martins Ayoola-Adeola, Karin Miller, Anil V Parwani, Floor J Backes, Ashley S Felix, Adrian A Suarez
OBJECTIVE: This study aims to determine the prevalence of programmed death ligand 1 (PD-L1) expression in endometrial carcinoma (EC) and determine clinical and pathological associations. METHODS: Immunohistochemistry for PD-L1 was performed on sections of a triple-core tissue microarray of 700 ECs. Positive PD-L1 expression, defined as 1% of cells staining positive, was evaluated in tumor and stromal compartments. Using age-adjusted logistic regression, we estimated odds ratios and 95% confidence intervals for associations between PD-L1 expression (overall and by staining compartment) with clinical and tumor characteristics...
October 20, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29053414/perk-phosphorylated-eif2%C3%AE-pathway-suppresses-tumor-metastasis-through-downregulating-expression-of-programmed-death-ligand-1-and-cxcl5-in-triple-negative-breast-cancer
#2
Weiwei Zou, Yu Bai, Xilong Wang, Kai Cheng, Hongguang Sun, Guoqiang Zhang, Xiaohong Wang, Zhenlin Yang
Endoplasmic reticulum (ER) stress has been reported to be associated with metastasis in many malignant tumors. PKR-like ER kinase-phosphorylated eukaryotic translation initiation factor 2α (PERK-p-eIF2α) pathway is one of the three main signal pathways in ER stress, however, its mechanism in regulating breast cancer (BC) relapse or metastasis was still not completely understood. Besides, drug resistance was an important factor influencing the effect of tumor treatment and whether PERK-p-eIF2α pathway was involved in the drug resistance to BC treatment also needs to be explored...
October 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/29053400/programmed-death-ligand-1-immunohistochemistry-testing-a-review-of-analytical-assays-and-clinical-implementation-in-non-small-cell-lung-cancer
#3
Reinhard Büttner, John R Gosney, Birgit Guldhammer Skov, Julien Adam, Noriko Motoi, Kenneth J Bloom, Manfred Dietel, John W Longshore, Fernando López-Ríos, Frédérique Penault-Llorca, Giuseppe Viale, Andrew C Wotherspoon, Keith M Kerr, Ming-Sound Tsao
Purpose Three programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are currently approved for treatment of non-small-cell lung cancer (NSCLC). Treatment with pembrolizumab in NSCLC requires PD-L1 immunohistochemistry (IHC) testing. Nivolumab and atezolizumab are approved without PD-L1 testing, though US Food and Drug Administration-cleared complementary PD-L1 tests are available for both. PD-L1 IHC assays used to assess PD-L1 expression in patients treated with programmed death-1/PD-L1 inhibitors in clinical trials include PD-L1 IHC 28-8 pharmDx (28-8), PD-L1 IHC 22C3 pharmDx (22C3), Ventana PD-L1 SP142 (SP142), and Ventana PD-L1 SP263 (SP263)...
October 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29053224/programmed-death-ligand-1-testing-of-lung-cancer-cytology-specimens-obtained-with-bronchoscopy
#4
Sean P Stoy, Lauren Rosen, Jeffrey Mueller, Septimiu Murgu
BACKGROUND: Programmed death-ligand 1 (PD-L1) expression testing is recommended by guidelines for patients with advanced non-small cell lung cancer (NSCLC). The primary objective of the current study was to determine the success rate of PD-L1 testing from cytology cell block samples obtained by bronchoscopic needle aspiration. The secondary objective was the assessment of the difference in specimen adequacy acquired via needles of different gauges. METHODS: Patients with NSCLC who underwent bronchoscopic needle aspirations for which PD-L1 testing was requested between November 1, 2016, and February 6, 2017, were included in the current analysis...
October 20, 2017: Cancer
https://www.readbyqxmd.com/read/29050367/expression-and-clinical-association-of-programmed-cell-death-1-programmed-death-ligand-1-and-cd8-lymphocytes-in-primary-sarcomas-is-subtype-dependent
#5
Anke E M van Erp, Yvonne M H Versleijen-Jonkers, Melissa H S Hillebrandt-Roeffen, Laurens van Houdt, Mark A J Gorris, Laura S van Dam, Thomas Mentzel, Marije E Weidema, C Dilara Savci-Heijink, Ingrid M E Desar, Hans H M Merks, Max M van Noesel, Janet Shipley, Winette T A van der Graaf, Uta E Flucke, Friederike A G Meyer-Wentrup
In order to explore the potential of immune checkpoint blockade in sarcoma, we investigated expression and clinical relevance of programmed cell death-1 (PD-1), programmed death ligand-1 (PD-L1) and CD8 in tumors of 208 sarcoma patients. Primary untreated osteosarcoma (n = 46), Ewing sarcoma (n = 32), alveolar rhabdomyosarcoma (n = 20), embryonal rhabdomyosarcoma (n = 77), synovial sarcoma (n = 22) and desmoplastic small round cell tumors (DSRCT) (n = 11) were examined immunohistochemically. PD-L1 expression was predominantly detected in alveolar and embryonal rhabdomyosarcomas (15% and 16%, respectively)...
September 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29050127/-immune-related-pneumonitis-caused-by-programmed-death-1-inhibitor-pembrolizumab-a-case-report-and-literature-review
#6
Y L Chen, J Zhao, R Jia, H Y Wang, J Zheng, C Q Bai, M Z Wang, J M Xu
Objective: To investigate the risk factors, clinical manifestations, radiological features, diagnosis, treatment and prognosis of immune-related pneumonitis caused by programmed death-1(PD-1)/PD-L1 inhibitors. Methods: The clinical data of immune-related pneumonitis caused by PD-1 inhibitor Pembrolizumab in a patient with advanced esophageal carcinoma admitted to the 307(th) Hospital of Chinese People's Liberation Army was retrospectively analyzed and the related literatures were reviewed. We searched Medline database using the keywords"PD-1 inhibitor","PD-L1 inhibitor","Pembrolizumab","Nivolumab","Atezolizumab"combined with"Pneumonitis"by Mar 31, 2017...
October 12, 2017: Chinese Journal of Tuberculosis and Respiratory Diseases
https://www.readbyqxmd.com/read/29049359/analysis-of-pd-1-expression-in-the-monocyte-subsets-from-non-septic-and-septic-preterm-neonates
#7
Magdalena Zasada, Marzena Lenart, Magdalena Rutkowska-Zapała, Małgorzata Stec, Wojciech Durlak, Andrzej Grudzień, Agnieszka Krzeczkowska, Nina Mól, Marta Pilch, Maciej Siedlar, Przemko Kwinta
Programmed death-1 (PD-1) receptor system represents a part of recently reported immunoregulatory pathway. PD-1 is an immune checkpoint molecule, which plays an important role in downregulating the immune system proinflammatory activity. Until recently, PD-1 expression was not established on immune cells of the preterm infants. The study objectives were to confirm expression of the PD-1 receptors on the monocytes isolated from very low birth weight newborns (VLBW), and to analyze their expression during the first week of life and late-onset sepsis...
2017: PloS One
https://www.readbyqxmd.com/read/29046141/generation-and-characterization-of-a-bispecific-antibody-targeting-both-pd-1-and-c-met
#8
Yi Wu, Min Yu, Zujun Sun, Weihua Hou, Yuxiong Wang, Qingyun Yuan, Wei Mo
Bispecific antibodies, BsAbs, are molecules with the ability to bind to two different epitopes on the same or different antigens. The goal of this study was to create a novel bispecific antibody targeting both cellular-mesenchymal to epithelial transition factor(c-MET) and programmed death-1(PD-1) as an anti-cancer therapeutic candidate. Upon binding to the c-MET antigen on a tumor cell and the PD-1 antigen on a T cell, a BsAb can redirect T cells for tumor killing. Based on the original sequences of PD-1 and c-MET mAbs, a BsAb gene was designed, and cloned into the pCEP4 vector...
October 17, 2017: Protein and Peptide Letters
https://www.readbyqxmd.com/read/29045540/phase-ii-trial-of-pembrolizumab-in-patients-with-platinum-refractory-germ-cell-tumors-a-hoosier-cancer-research-network-study-gu14-206
#9
N Adra, L H Einhorn, S K Althouse, N R Ammakkanavar, D Musapatika, C Albany, D Vaughn, N H Hanna
Background: Despite remarkable results with salvage standard-dose or high-dose chemotherapy about 15% of patients with relapsed germ-cell tumors (GCT) are incurable. Immune checkpoint inhibitors have produced significant remission in multiple tumor types. We report the first study of immunotherapy in patients with GCT. Patients and Methods: Single arm phase 2 trial investigating pembrolizumab 200mg IV Q3weeks until disease progression in patients with relapsed GCT and no curable options...
October 17, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29045188/rapid-evolution-of-thyroid-dysfunction-in-patients-treated-with-nivolumab
#10
Grenye O'Malley, Hanna J Lee, Samir Parekh, Matthew D Galsky, Cardinale B Smith, Philip Friedlander, Robert T Yanagisawa, Emily J Gallagher
OBJECTIVE: To describe the evolution of thyroid dysfunction in a series of patients with cancer treated with the immune checkpoint inhibitor anti-programmed cell death protein-1 (PD-1) monoclonal antibody, nivolumab. METHODS: Cases of thyroid dysfunction after initiation of checkpoint inhibitor treatment were identified from the Division of Endocrinology clinical practice at Mount Sinai Hospital, New York from April 2016 to February 2017. Charts were reviewed to identify patients treated with nivolumab with new onset of thyroid dysfunction...
October 2017: Endocrine Practice
https://www.readbyqxmd.com/read/29041905/clinicopathological-and-prognostic-significance-of-programmed-death-ligand-1-expression-in-breast-cancer-a-meta-analysis
#11
Hye Min Kim, Jinae Lee, Ja Seung Koo
BACKGROUND: Programmed cell death-ligand 1 (PD-L1) may be a useful molecule for targeted immunotherapy. Therefore, this meta-analysis aimed to investigate PD-L1 expression in breast cancer and its associations with clinicopathological factors and outcomes, which may help determine whether PD-L1 expression is a useful prognostic marker. METHODS: The Medline Ovid, Cochrane, PubMed, Google Scholar, and Web of Knowledge databases were searched for studies that evaluated the prognostic or clinicopathological significance of PD-L1 expression in patients with breast cancer, and reported at least one survival-related outcome...
October 17, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29036791/globo-h-expression-is-associated-with-driver-mutations-and-pd-l1-expressions-in-stage-i-non-small-cell-lung-cancer
#12
Ching-Yao Yang, Mong-Wei Lin, Yih-Leong Chang, Chen-Tu Wu
BACKGROUND: Globo H is a tumor-associated carbohydrate antigen exclusively expressed in cancer cells rather than normal tissue. Globo H has been found on many cancers of epithelial origins, and become an attractive target for cancer vaccine. OBJECTIVES: We aimed to study the expression of Globo H in non-small cell lung cancer (NSCLC) patients, and correlated its expression with common driver mutations, clinical outcomes, and status of immune checkpoint, programmed death-ligand 1 (PD-L1)...
September 29, 2017: Cancer Biomarkers: Section A of Disease Markers
https://www.readbyqxmd.com/read/29034589/involvement-of-local-renin-angiotensin-system-in-immunosuppression-of-tumor-microenvironment
#13
Kenta Nakamura, Tomonori Yaguchi, Gaku Ohmura, Asuka Kobayashi, Naoshi Kawamura, Takashi Iwata, Yukiko Kiniwa, Ryuhei Okuyama, Yutaka Kawakami
To improve the current cancer immunotherapies, strategies to modulate various immunosuppressive cells including myeloid derived suppressor cells (MDSCs) which were shown to be negative factors in the immune-checkpoint blockade therapy, need to be developed. In this study, we have evaluated the role of local renin-angiotensin system (RAS) in the tumor immune-microenvironment using murine models bearing tumor cell lines in which RAS was not involved in their proliferation and angiogenetic ability. Administration of angiotensin II receptor blockers (ARBs) to C57BL/6 mice bearing murine colon cancer cell line MC38 resulted in significant enhancement of tumor antigen gp70 specific T cells...
October 16, 2017: Cancer Science
https://www.readbyqxmd.com/read/29034543/pd-l1-expression-is-mainly-regulated-by-ifn-%C3%AE-associated-with-jak-stat-pathway-in-gastric-cancer
#14
Kousaku Mimura, Jun Liang Teh, Hirokazu Okayama, Kensuke Shiraishi, Ley-Fang Kua, Vivien Koh, Duane T Smoot, Hassan Ashktorab, Takahiro Oike, Yoshiyuki Suzuki, Zul Fazreen, Bernadette R Asuncion, Asim Shabbir, Wei-Peng Yong, Jimmy So, Richie Soong, Koji Kono
Despite multidisciplinary treatment for patients with advanced gastric cancer, their prognosis still remains poor. Therefore, the development of novel therapeutic strategies is urgently needed, and immunotherapy utilizing anti-programmed death 1/-programmed death ligand-1 mAb is an attractive approach. However, as there is limited information on how programmed death ligand-1 is upregulated on tumor cells within the tumor microenvironment, we examined the mechanism of programmed death ligand-1 regulation with a particular focus on interferon gamma in in-vitro setting and in clinical samples...
October 16, 2017: Cancer Science
https://www.readbyqxmd.com/read/29031195/ginsenoside-rg3-attenuates-cisplatin-resistance-in-lung-cancer-by-downregulating-pd-l1-and-resuming-immune
#15
Zhansheng Jiang, Yanfang Yang, Yinli Yang, Yu Zhang, Zhensong Yue, Zhanyu Pan, Xiubao Ren
Programmed death ligand 1 (PD-L1) as one the most important immune checkpoint was verified to involve in chemotherapy resistance in non-small cell lung cancer (NSCLC). Ginsenoside Rg3 is isolated from Chinese herb-Panax ginseng which is recognized to boost immune and has anti-cancer activity against a majority of carcinomas including NSCLC. In this study, we aim to identify whether Rg3 could attenuate the PD-L1 expression induced by resistance to cisplatin and draw out the underlying mechanisms of PD-L1 in this process...
October 11, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29029530/which-treatment-is-preferred-for-advanced-non-small-cell-lung-cancer-with-wild-type-epidermal-growth-factor-receptor-in-second-line-therapy-a-meta-analysis-comparing-immune-checkpoint-inhibitor-tyrosine-kinase-inhibitor-and-chemotherapy
#16
Di Wu, Chongyang Duan, Fenfang Wu, Liyong Chen, Size Chen
BACKGROUND: The recommendations regarding the optimum treatment for advanced non-small-cell lung cancer (NSCLC) patients with wild-type (WT) epidermal growth factor receptor (EGFR) tumors remain unclear. This meta-analysis was conducted to assess the efficacy among programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1) antibody, EGFR-tyrosine kinase inhibitors (TKI) and chemotherapy in second-and third-line therapy. PATIENTS AND METHODS: Randomized trials investigating two of the three treatments were searched and included...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29029512/pd-l1-expression-indicates-favorable-prognosis-for-advanced-lung-adenocarcinoma-patients-treated-with-pemetrexed
#17
Pei Zhang, Zhang Bao, Liming Xu, Jianya Zhou, Guohua Lu, Yinan Yao, Rong Liu, Qiqi Gao, Yihong Shen, Jianying Zhou
Conventional chemotherapy for lung cancer exerts anti-tumor effects through cytotoxicity, and through immunologic regulation by reducing specific T cell subsets and inducing the expression of programmed death ligand 1 (PD-L1) on tumor cells. Even though pemetrexed has shown huge potential in combination with other targeted or immune therapies, there is still little information about the values of specific immune checkpoint markers for advanced lung adenocarcinoma treated with pemetrexed. In the present study, a total of 56 patients with advanced lung adenocarcinoma, who received pemetrexed-based chemotherapy, were included retrospectively...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29029297/cytomegalovirus-specific-t-cell-transfer-for-refractory-cytomegalovirus-infection-after-haploidentical-stem-cell-transplantation-the-quantitative-and-qualitative-immune-recovery-for-cytomegalovirus
#18
Xu-Ying Pei, Xiang-Yu Zhao, Ying-Jun Chang, Jing Liu, Lan-Ping Xu, Yu Wang, Xiao-Hui Zhang, Wei Han, Yu-Hong Chen, Xiao-Jun Huang
Background: The efficiency and mechanisms of adoptive transfer of cytomegalovirus (CMV)specific T cells for refractory CMV infection after haploidentical stem cell transplantation (haplo-SCT) remain largely unknown. Methods: Thirty-two patients with refractory CMV infection who accepted treatment with adoptive CMV-specific T-cell infusion following haplo-SCT were prospectively enrolled. Another 32 patients with nonrefractory CMV infection after haplo-SCT were selected as control subjects...
September 23, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29028305/fast-image-guided-stratification-using-anti-programmed-death-ligand-1-gold-nanoparticles-for-cancer-immunotherapy
#19
Rinat Meir, Katerina Shamalov, Tamar Sadan, Menachem Motiei, Gur Yaari, Cyrille J Cohen, Rachela Popovtzer
Cancer immunotherapy has made enormous progress in offering safer and more effective treatments for the disease. Specifically, programmed death-ligand 1 antibody (αPDL1), designed to perform immune checkpoint blockade (ICB), is now considered a pillar in cancer immunotherapy. However, due to the complexity and heterogeneity of tumors, as well as the diversity in patient response, ICB therapy has only a 30 percent success rate, at most; moreover, the efficacy of ICB can be evaluated only two months after start of treatment...
October 13, 2017: ACS Nano
https://www.readbyqxmd.com/read/29027395/prognostic-value-of-programmed-death-ligand-1-pd-l1-expression-in-ovarian-clear-cell-carcinoma
#20
Jun Zhu, Hao Wen, Rui Bi, Yong Wu, Xiaohua Wu
OBJECTIVE: Programmed death-ligand 1 (PD-L1) was expressed in various tumors and antibodies targeting its receptor programmed cell death-1 (PD-1) are emerging cancer therapeutics. This study was designed to evaluate the expression of PD-L1 and its correlation with clinicopathologic features and clinical outcomes in ovarian clear cell carcinoma (OCCC). METHODS: The PD-L1 expression was measured by tissue-microarray-based immunohistochemistry from 122 eligible patients diagnosed with OCCC...
November 2017: Journal of Gynecologic Oncology
keyword
keyword
114957
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"